drugset / Trial / NCT05046548
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
Phase 1/2
Completed
400 enrolled
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
RandomizedParallel-groupDouble-blindPrevention
Summary
Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI "Chumakov FSC R\&D IBP RAS", on adult volunteers aged 18-60" (Clinical trials, phase I/II). Study purpose is to assess the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified coronavirus vaccine sorbed on adult volunteers aged 18-60.
Timeline
- Start
- 2020-10-03
- Primary completion
- 2020-10-15
- Completion
- 2021-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoviVac | Vaccine | 0.5 ml | Intramuscular |